NEW YORK, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Veteran business journalist Kelsey Hubbard joins Doug Swirsky, Chief Executive Officer, GenVec, Inc. [GNVC] to discuss the company's industry, strategy, financials and positioning.
Click here to view video:
http://www.nasdaq.com/article/genvec-inc-gnvc-interview-with-doug-swirsky-ceo-cm447829
Doug Swirsky, Chief Executive Officer:
Douglas J. Swirsky, has served as the President and Chief Executive Officer and as a director of the Company since September 2013. He joined GenVec in 2006 as Chief Financial Officer, Corporate Secretary and Treasurer; and continues to serve as Corporate Secretary. Prior to joining the Company, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial's acquisition of the Legg Mason Capital Markets business in 2005. Mr. Swirsky, a Certified Public Accountant and CFA® charterholder, previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a member of the Board of Directors of Fibrocell Science, Inc.
About GenVec, Inc.:
GenVec is an entrepreneurial clinical-stage biopharmaceutical company focused on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product, CGF166, is licensed to Novartis and currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, the company also licenses its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 888/534-0565.